Elevations of plasma total or LDL cholesterol are major risk factors for cardiovascular disease. Efforts directed at preventing and treating cardiovascular disease have often focused on reducing the levels of these substances in the blood. 
1. Abbreviations used in this paper: Adv/RSV-hAAT, recombinant adenovirus containing human a,-antitrypsin CDNA under transcriptional control of RSV long terminal repeat; Adv/RSV-rbLDLR, recombinant adenovirus containing rabbit LDL receptor CDNA under transcriptional control of RSV long terminal repeat; CE, cholesteryl ester; CETP, cholesteryl ester transfer protein; CHD, Coronary heart disease; EHL-WHHR, English half-lop rabbits bearing the Watanabe heritable hyperlipidemic rabbit trait; EHL-ww, English half-lop rabbit; FH, familial hypercholesterolemia; LTR, long terminal repeat; NZW, New Zeland white; RSV, Rous sarcoma virus.
Hypercholesterolemia contributes to a number of human diseases, including coronary atherosclerosis, myocardial infarction, and stroke. Identification of the molecular defect that causes familial hypercholesterolemia (FH),' one of the most devastating of the lipid disorders, has provided insight into lipid metabolism and aided in the development of new treatments for hyperlipidemia and atherosclerosis. In normal individuals, plasma LDL is cleared primarily via LDL receptors on the surface of hepatocytes. In FH patients, LDL is cleared much more slowly than normal because of mutations in the LDL receptor gene that block the synthesis or transport of the LDL receptor to the cell surface, inhibit LDL binding to the receptor, or prevent internalization of the LDLI/receptor complex (1) . FH heterozygotes, who comprise 1 out of every 500 individuals in the U.S. population, exhibit twofold elevations in plasma cholesterol levels and often begin to develop tendon xanthomas and coronary atherosclerosis in their twenties (2) . FH homozygotes, who comprise one out of every one million individuals in the U.S. population, exhibit fourfold elevations in plasma cholesterol levels, often develop cutaneous xanthomas before 4 yr of age, display well-developed coronary heart disease in childhood, and frequently die before age 20 (3, 4) .
Current treatments for FH heterozygotes have focused on upregulating expression of the normal LDL receptor gene (5) . For example, drugs that block bile acid recycling and cholesterol biosynthesis reduce intracellular cholesterol levels and result in upregulation of LDL receptor gene expression, leading to a decrease in plasma cholesterol levels (6) (7) (8) . This mode of therapy is much less effective in FH homozygotes, because neither copy of the LDL receptor gene produces a fully functional receptor. These patients have been treated by plasma exchange for removal of LDL (9) or by portacaval anastomosis (10) (21) . The resultant cDNA fragment was cloned into the EcoRV site of the ElA-adenovirus transfer vector pAdLl/RSV (22, 23) . This construct was cotransfected with the plasmid pJM17 into the adenovirus packaging cell line 293. Recombinant adenovirus clones were plaque purified and amplified as previously described (24) . The viral titer, as determined by OD, varied from 1 to 3 x 10 " particles/ml.
Rabbit LDL receptor functional assay. In vitro binding, uptake, and degradation of '"I-labeled human LDL by primary hepatocytes of
Watanabe rabbits was measured after transduction by Adv/RSVrbLDLR in vitro to confirm the function of the rbLDLR cDNA. Watanabe rabbit hepatocytes were isolated and cultured in SUM medium (tyrosine-free MEM/Waymouth's supplemented with growth factors) overnight (25) . The hepatocytes were transduced with Adv/RSVrbLDLR at 0, 1, 10, and 100 particles/cell for 4 h. The medium was then changed and the cells were cultured overnight. Binding, uptake, and degradation of "I-labeled human LDL were measured as described (26, 27) . In vivo delivery ofrecombinant adenovirus via splenic vein infusion. New Zealand white (NZW) rabbits were anesthetized with 0.5 ml/kg of an anesthetic containing a combination of ketamine (1.43 mg/ml), xylazine (0.286 mg/ml), and acepromazine (0.047 mg/ml). EHL-WHHR rabbits were anesthetized using the respiratory anesthetic Aerrane (isoflurane). Recombinant adenovirus suspended in buffer (10 mM Tris-Cl, 1 mM MgCl2, 10% glycerol) was diluted with PBS to 10 ml and then infused through splenic vein injection.
To test LDL receptor gene expression in vivo, the adenovirus Adv/ RSV-rbLDLR was infused into the portal circulation of Watanabe rabbits. Hepatocytes were isolated from these rabbits 3 d postinfusion, and the binding and uptake of '"I-labeled human LDL were measured as described above. Hepatocytes from rabbits infused with a recombinant adenovirus bearing the human a,-antitrypsin gene (Adv/RSV-hAAT) (28) were used as a negative control.
Virus transfection efficiency and tissue distribution. 0, 1 X 101, 2 x 1011, 4 x 10 " Adv/RSV-,3gal particles/kg body weight were infused into NZW rabbits. 3 d after infusion, hepatocytes were isolated and stained for ,B-galactosidase activity as previously described (29) to determine the in vivo transduction efficiency. A sample of liver tissue was also collected at this time for histopathological analysis. At 1 or 4 wk postinfusion, 10 different tissue types were collected. Genomic DNA was extracted from frozen tissue samples, and serial dilutions containing 1 og to 1 ng were used as templates in a semiquantitative PCR assay to determine the presence of Adv/RSV-,/gal DNA as previously described (24) . DNA isolated from 1 to 106 viral particles was amplified in parallel as positive controls. A 500-bp PCR product was generated from amplification with primers located in the RSV promoter (5 '-GTAAGG-TGGTACCATCGT-3') and the /-galactosidase gene (5'-GGATGT-GCTGCAAGGCGA-3'). Viral DNA copy numbers per cell were determined by comparing the band density of these products on agarose gel to those of PCR products from the positive controls.
Plasma total, HDL and LDL cholesterol, and apo AI determinations. Six sets of age-and sex-matched Watanabe rabbits were infused with recombinant Adv/RSV-rbLDLR, Adv/RSV-hAAT, or buffer through splenic vein injection. Plasma cholesterol level was determined twice weekly both pre-and postinfusion in all animals. Rabbits infused with Adv/RSV-hAAT and buffer served as negative controls. Total plasma cholesterol levels were determined by an enzymatic method using the Cholesterol/HP kit from Boehringer-Mannheim Diagnostics (Indianapolis, IN) in a 704 Analyzer (Hitachi Sci. Instrs., Mountain View, CA). HDL-cholesterol level was measured from the supernatant after precipitating the other plasma lipoproteins with 0.05 M MgCl2 and 0.05% dextran sulfate (30) . An ELISA with a goat anti-rabbit apo Al IgG from Parke-Davis (Ann Arbor, MI) was used to determine serum apo AI levels (31 18 Watanabe rabbits were divided into 6 age-and sex-matched sets. One member of each set received a splenic vein infusion of either 4 x 1011 particles/kg of Adv/RSV-rbLDLR, Adv/RSV-hAAT, or the buffer in which the viruses were suspended. 6 d after treatment, plasma total cholesterol in the animals treated with Adv/RSV-rbLDLR was significantly decreased as compared with the pretreatment levels (825.5±69.8 mg/dl at day -1 vs. 247.3±61.5 mg/dl at day 6; P < 0.001) (Fig. 2) . These levels were also significantly lower than those observed in either Adv/RSV-hAAT-treated control group (638.8±53.6 mg/dl at day 6, P < 0.001) or the buffertreated control group (696.0±124.1 mg/dl at day 6, P < 0.001), despite a small but significant decrease in plasma total cholesterol levels that also occurred in these latter two 4 .0±0.0 mg/dl (day 0); P < 0.005] or to those observed in either the Adv/RSV-hAAT-treated control group (5.3±3.0 mg/dl, P < 0.002) or the buffer-treated group (3.3±3.0 mg/ dl, P < 0.001) (Fig. 3) . At this same time point, apo AI levels 770 Li et al. Each treatment group contained four age-and sex-matched animals. Multiple determinations were made before infusion to establish pretreatment levels. Blood samples were drawn twice weekly after infusion and HDL-cholesterol levels were determined. By 10 d postinfusion, HDL- cholesterol levels in the rabbits treated with Adv/RSV-rbLDLR were significantly reduced (P < 0.01) relative to those treated with Adv/ RSV-hAAT or buffer. Standard errors are indicated for each data point.
in animals treated with Adv/RSV-rbLDLR (6.44±0.34 mg/dl) were also significantly increased relative to those infused with either Adv/RSV-hAAT (0.97±0.66 mg/dl, P < 0.001) or buffer (1.54±0.94 mg/dl, P < 0.005) (Fig. 4) . HDL cholesterol and apo AI both returned to within the pretreatment range by 3 wk. This effect was specific for the rbLDLR gene, because it was not observed in buffer-or control virus-treated groups.
Although the lowest plasma cholesterol levels were reached in the Watanabe rabbits 6 d after delivery of the rbLDLR gene, the highest plasma HDL-cholesterol levels were reached at 10 d posttreatment.
Decrease of LDL cholesterol after adenovirus-mediated LDL receptor gene delivery in vivo. FPLC was combined with enzymatic methods to determine the relative contributions of LDL-, HDL-, and VLDL-cholesterol changes to the observed decreases in total cholesterol levels. Serum samples were analyzed from one EHL-ww rabbit (the EHL-WHHR genetic background strain) and from Watanabe rabbits before and at 6 and 10 d after treatment with Adv/RSV-rbLDLR, Adv/RSV-hAAT, or buffer (Fig. 5) . LDL receptor deficiency in the EHL-WHHR rabbit caused a large increase in the LDL-cholesterol level and a large decrease in the HDL-cholesterol level as compared with the non-LDLR-deficient EHL-ww rabbit (Fig. 5, a and b) . 6 d after Adv/RSV-LDLR infusion (Fig. Sa) , LDL-cholesterol levels in the EHL-WHHR animal decreased by 75% relative to pretreatment levels (732.9 mg/dl at day -1 vs. 211.5 mg/dl at day 6), and this drop in LDL-cholesterol levels was the major contributor to the decrease in total cholesterol. No LDL-cholesterol decreases occurred in either of the control animals (data not shown). LDL receptor gene delivery also increased the plasma HDL-cholesterol level in Watanabe rabbits by 300% at 10 d posttreatment (8.7 mg/dl at day -I vs. 28.2 mg/dl at day 10) (Fig. Sb) , a level nearly identical to that found in the EHLww rabbit.
Discussion
Adenovirus-mediated gene delivery has been shown to be an efficient method for in vivo gene delivery in mouse and dog models by our laboratory and others (19, 23, 24, 29, 34, 35) . In this study, the efficiency of direct gene transfer of the rabbit LDL receptor into the liver of Watanabe rabbits was examined as a model of gene therapy for hyperlipidemia. The resulting decreases in plasma total cholesterol levels from 825.5±69.8 to 247.3±61.5 mg/dl after gene delivery demonstrates the feasibility of gene therapy for FH by in vivo delivery of Adv/RSVrbLDLR. As in other systems involving adenoviral-mediated gene delivery in vivo (14, 19, 23, 24, 29, 34) , the therapeutic effect was transient in these rabbits. Although long-term therapeutic effects may be achievable with adenoviral vectors modified for increased persistence, the current study illustrates the principle that hyperlipidemia can be ameliorated by a single inoculation of a vector containing a therapeutic gene.
Previous studies on adenovirus-mediated LDL receptor gene delivery have shown increased clearance of '"'I-VLDL in LDL receptor knockout mice ( 14) , resulting in a complete reduction of plasma LDL and decreased total cholesterol in Watanabe rabbits (19) . In the present study, we observed not only a significant decrease in total cholesterol but also observed a significant elevation of plasma HDL cholesterol in the Watanabe rabbits treated with the rabbit LDL receptor. Similar increases in HDL cholesterol were not observed in the mouse model ( 14) . Although the mechanisms responsible for this increase in HDL cholesterol are not clear, the reduction of the LDL pool caused by the treatment with the LDL receptor may limit the transfer of cholesterol from HDL to LDL that is mediated by cholesteryl ester transfer protein (CETP). CETP transfers cholesterol esters from HDL particles to less dense apo B-containing lipoprotein in exchange for triglyceride. It is highly active in both human and rabbits (36) but is apparently inactive in mice (37) . CETP activity correlates directly with the LDL-cholesterol level and inversely with HDLcholesterol level. As a result, normal mice have very low LDLand high HDL-cholesterol levels (14) , whereas humans and rabbits display a relatively high LDL:HDL ratio. Although HDL levels remain unaltered after LDL receptor knockout in mice ( 14) , HDL levels are greatly reduced in LDL receptor-deficient rabbits (Fig. 5, a and b) . LDL (39) .
After LDL receptor gene delivery to the Watanabe rabbit, the LDL pool was decreased. As a secondary effect of decreased transfer of HDL cholesterol to LDL, HDL-cholesterol levels were increased. This conclusion is supported by the fact that plasma total cholesterol reached its lowest level 6 d postinfusion, whereas HDL cholesterol peaks at 10 d postinfusion. The conclusion is further supported by the fact that human FH patients in an earlier study exhibited a transient elevation of plasma HDL cholesterol after plasma LDL cholesterol was reduced by plasmapheresis (40) , and that no change in HDLcholesterol levels were observed after in vivo gene delivery of the LDL receptor in LDL receptor knockout mice.
Watanabe rabbits exhibit lower apo AI levels than normal rabbits because of an increase in the rate of apo AI degradation and a decrease in rate of synthesis (41) . The increase in apo AI levels after gene delivery in our experiment could be the result of increased apo Al synthesis. Alternatively, a reduction in the transfer of CE to apo B-containing particles would reduce the clearance of HDL particles, leading to an increase in apo AI.
In epidemiologic studies, there is a strong positive correlation between the level of LDL cholesterol and coronary heart disease (CHD) (42, 43) . High HDL cholesterol, on the other hand, is thought to reduce the risk of CHD (44). Clinically, the ratio of total cholesterol:HDL cholesterol has proven to be the most reliable indicator of CHD risk. As a result, most CHD therapies have focused on decreasing total cholesterol or increasing HDL cholesterol. Our results demonstrate that there may be an inverse relationship between plasma LDL cholesterol and HDL cholesterol and suggest that reducing LDL-cholesterol levels may further benefit homologous LDL receptor deficient patients by upregulating plasma HDL-cholesterol levels.
